CNS and Oncology Continue to Drive Multi-Site Momentum
The February 2026 edition of IndiaTrialPulse by StriderDCT tracked emerging trends from multi-site trials registered on the Clinical Trials Registry of India (CTRI).
Key Highlights
- 42 multi-site trials were registered during February
- CNS and Oncology led therapeutic activity
- Indian Pharma remained the leading sponsor category
- Tier 2 cities demonstrated strong site participation
- India-only studies continued to dominate registrations
What This Indicates
- February reflected increasing operational maturity within India’s clinical trial landscape.
- The strong contribution from Tier 2 cities suggests gradual decentralization of clinical research activity, while therapeutic diversification indicates broader clinical development focus areas.
- IndiaTrialPulse continues to decode these evolving ecosystem signals through consistent monthly tracking.
